Investment Thesis
TransMedics exhibits strong revenue growth (+37.1% YoY) and healthy gross margins (58.2%), indicating solid product-market fit in the medical device sector. However, negative free cash flow (-$12.1M) despite positive net income, combined with extremely poor capital efficiency (ROE 1.5%, ROA 0.5%), raises concerns about earnings quality and the sustainability of profitability given high capital intensity.
Strengths
- Strong revenue growth of 37.1% YoY demonstrates robust market demand
- Healthy gross margin of 58.2% indicates pricing power and cost management
- Fortress balance sheet with $461.7M cash, minimal debt ($58.8M), and 6.74x current ratio provides strategic flexibility
Risks
- Negative free cash flow of -$12.1M despite positive net income signals cash conversion problems and high capex burden relative to operating cash flow
- Extremely low returns on capital (ROE 1.5%, ROA 0.5%) indicate poor capital deployment efficiency and value creation
- Low interest coverage ratio of 1.8x and thin net margin of 4.2% limit financial flexibility despite strong balance sheet
Key Metrics to Watch
- Free cash flow sustainability and capex intensity relative to revenue growth
- Operating cash flow conversion rates and cash-to-earnings quality
- Return on equity and asset turnover trends as profitability scales
Financial Metrics
Revenue
173.9M
Net Income
7.3M
EPS (Diluted)
$0.20
Free Cash Flow
-12.1M
Total Assets
1.4B
Cash
461.7M
Profitability Ratios
Gross Margin
58.2%
Operating Margin
7.6%
Net Margin
4.2%
ROE
1.5%
ROA
0.5%
FCF Margin
-7.0%
Balance Sheet & Liquidity
Current Ratio
6.74x
Quick Ratio
6.19x
Debt/Equity
0.12x
Debt/Assets
65.6%
Interest Coverage
1.84x
Long-term Debt
58.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-07T10:49:33.040195 |
Data as of: 2026-03-31 |
Powered by Claude AI